Clinical Trials · NCT01280344
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Enrollment
- 320
- Start date
- Apr 2011
- Locations
- 45 sites, United States
- Primary endpoint
- Recovery of Gastrointestinal (GI) Function